Hypotension News and Research

RSS

AMR finds 75 percent of hetastarch recipients underwent surgical procedures

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%).

19 Sep 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

FDA approve Fanapt tablets (iloperidone) to treat adults with schizophrenia

The U.S. Food and Drug Administration has approved Fanapt tablets (iloperidone) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder.

7 May 2009

Children as young as five with life threatening anorexia

New research by Australian experts has revealed that children as young as five are being treated for eating disorders - the researchers say in some cases the eating disorder has reached the stage that forced feeding becomes necessary in order to save their lives.

20 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Haemofiltration significantly reduces ECMO duration in newborns

Haemofiltration has already been shown to improve fluid balance in children treated with extracorporeal membrane oxygenation (ECMO) but now researchers writing in BioMed Central's open access journal Critical Care have reported that continuous haemofiltration significantly reduces ECMO duration in newborns.

1 Apr 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

FDA approves Lusedra (fospropofol disodium) injection for monitored anesthesia care sedation

Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved Lusedra (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

14 Dec 2008

Use of rapid response team in hospital not linked with reduction in cardio arrests or deaths

Although there is an effort to implement rapid response teams in hospitals throughout the country, new research suggests that they do not result in a reduced rate of cardiopulmonary arrests or deaths, according to a study in the December 3 issue of JAMA.

3 Dec 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

Link between dementia and hypotension - Alzheimer's sufferers might have lower blood pressure

A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer's disease experience a reduction in their high blood pressure because of cognitive decline.

14 Oct 2008

Why sufferers from Alzheimer's disease might have lower blood pressure

A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer’s disease experience a reduction in their high blood pressure because of cognitive decline.

14 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

New biomarkers in acute cardiac care

In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.

1 Sep 2008

Beta blockers after surgery more risky than beneficial

The results of new research has shown that patients given high doses of beta blocker drugs following non-cardiac surgery were more likely to have a stroke or die. However they were less likely to suffer a heart attack.

13 May 2008